| Management target | Revenue FY27 |
|---|
| Revenue growth | 39.7% YoY; 6% QoQ growth. Strongest Q1 in 4 years. |
|---|---|
| Margins | Sequential EBITDA margin at 16.9%; targeting 19-20% by Q4 FY27. |
| Order book | Robust; 105 active clients. Large tectonic deals ramping up. |
| Demand visibility | Positive; clients excited by AI, though enterprise adoption remains measured. |
| Management confidence | Confident, shifting from optimism to conviction regarding GenAI and scale. |
Growth
Revenue grew 39.7% YoY; 6% QoQ. Growth is high-quality, driven by accounts beyond top 20.
Outlook
EBITDA margins expected to return to 19-20% by Q4 FY27 as revenue scales.
Risks
Margins are under pressure from upfront tectonic deal costs and workforce transformation expenses.
Last quarter's promises, checked
Delivered
- Revenue ₹3,500cr+ FY26 → ₹35,105M (= BEAT)
- Q4 Revenue ₹1,000cr+ → ₹10,000M (= BEAT)
- Active customers 73 to 91 → 105 (= BEAT)
Partly delivered
- DSO 63 days → 60s to 70s guidance (= PARTIAL)
Missed
- EBITDA margin 19-20% → 16.9% (= MISS)
Earnings Call Transcript filed with BSE, NSE: INDGN. Summary written with AI assistance from the document.
Indegene Ltd: key numbers
- Share price
- ₹596.30
- Market cap
- ₹14,366 Cr
- Revenue (annual)
- ₹3,510 Cr
- Net profit (annual)
- ₹401.1 Cr
- P/E (TTM)
- 35.8×Sector 53.1×
- Promoter holding
- 0.00%+0.00% QoQ
- FII holding
- 9.92%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indegene Ltd
All →Indegene Business Update
Indegene Limited hosted its Indegene Digital Summit 2026, focusing on operationalizing AI within life sciences. The event also featured the presentation of the VITAL Awards 2026.
Indegene Merger & Restructuring
Indegene Limited completed the internal merger of its two indirect wholly owned subsidiaries in Germany. This reorganization does not impact Indegene's financial position or operations.
Indegene Legal & Regulatory
Indegene Limited received preliminary court approval for a class action settlement related to the U.S. Telephone Consumer Protection Act. Final hearing is scheduled for January 2027.
Indegene Legal & Regulatory
The U.S. Court preliminarily approved the class action settlement for Indegene's subsidiary. The maximum settlement fund is approximately ₹44.84 Crore.
- Value
- ₹44.84 Cr
Indegene Legal & Regulatory
Indegene Limited's subsidiary, Indegene Inc., finalized a class-action settlement framework regarding U.S. fax communication violations. The maximum potential settlement fund is USD 4.72 million (₹44.84 Crore).
- Value
- ₹44.84 Cr
Indegene Legal & Regulatory
Indegene Limited's subsidiary finalized a USD 4.72 million class-action settlement agreement regarding U.S. TCPA violations. The settlement, involving approximately 18,851 unique fax numbers, remains subject to court approval.
- Value
- ₹45.24 Cr